Kezar Life Sciences (KZR) Price & Analysis

Compare

471 Followers

KZR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.62 - $9.18

Previous CloseN/A

Volume19.48K

Average Volume (3M)65.13K

Market Cap

$29.73M

Enterprise Value-$64.60M

Total Cash (Recent Filing)$114.36M

Total Debt (Recent Filing)$14.11M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding7,305,800

10 Day Avg. Volume50,950

30 Day Avg. Volume65,127

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-2.17

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit247.51

Enterprise Value/Ebitda0.85

Forecast

1Y Price Target

$7.00

Price Target Upside70.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPositive topline results from zeto's Phase II trial in AIH with 51% of patients on zeto achieving a complete response compared to 37% on placebo.

Market OpportunityRemoval of the clinical hold and alignment on the next development steps for zeto in AIH will provide upside to current share prices given the blockbuster market opportunity.

Regulatory ProgressThe FDA lifted the partial clinical hold on the Phase II PORTOLA study evaluating zetomipzomib in patients with autoimmune hepatitis.

Bears Say

Regulatory UncertaintyIt is difficult to know when the partial clinical hold may be resolved and what data might be required to address the agency's concerns.

Stock PerformanceShares are down 36% year-to-date as investors still have questions and key debates on the partial clinical hold and the AIH regulatory path haven't been addressed.

Kezar Life Sciences News

Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial

The company states: “Kezar Life Sciences (KZR) announced that the Division of Hepatology and Nutrition of the U.S....

24d ago

KZR

Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties

H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on KZR stock, giving a Hold rating yesterday....

23d ago

KZR

Kezar Life Sciences Holds Annual Stockholders Meeting

Kezar Life Sciences ( ($KZR) ) has shared an update. On June 17, 2025, Kezar Life Sciences held...

2M ago

KZR

Kezar Life Sciences Reports Positive Trial Results

Kezar Life Sciences ( ($KZR) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

KZR

Kezar Life Sciences: Promising Phase II Results and Strategic Developments Support Buy Rating

William Blair analyst Matt Phipps has reiterated their bullish stance on KZR stock, giving a Buy rating today....

3M ago

KZR

Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)

Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025, compared to $132.2 million...

3M ago

KZR

Kezar Life Sciences Appoints New Principal Accounting Officer

Kezar Life Sciences ( ($KZR) ) has shared an update. On March 27, 2025, Kezar Life Sciences announced...

4M ago

KZR

Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating

Analyst Maury Raycroft of Jefferies maintained a Buy rating on Kezar Life Sciences (KZR – Research Report), with...

4M ago

KZR

Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Kezar Life Sciences (KZR) to $7 from...

5M ago

KZR

Kezar Life Sciences Reports Promising AIH Trial Results

Kezar Life Sciences ( ($KZR) ) has released its Q4 earnings. Here is a breakdown of the information...

5M ago

KZR

Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KZR stock, giving a Buy rating today....

5M ago

KZR

Kezar Life Sciences reports topline results from PORTOLA trial

Kezar Life Sciences (KZR) reported topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a selective...

5M ago

KZR

Kezar Life Sciences files $400M mixed securities shelf

17:20 EST Kezar Life Sciences (KZR) files $400M mixed securities shelf Published first on TheFly – the ultimate...

6M ago

KZR

Kezar Life Sciences price target lowered to $9 from $11 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Kezar Life Sciences (KZR) to $9 from...

8M ago

KZR

KZR FAQ

What was Kezar Life Sciences’s price range in the past 12 months?

Kezar Life Sciences lowest stock price was $3.62 and its highest was $9.18 in the past 12 months.

What is Kezar Life Sciences’s market cap?

Kezar Life Sciences’s market cap is $29.73M.

When is Kezar Life Sciences’s upcoming earnings report date?

Kezar Life Sciences’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Kezar Life Sciences’s earnings last quarter?

Currently, no data Available

Is Kezar Life Sciences overvalued?

According to Wall Street analysts Kezar Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kezar Life Sciences pay dividends?

Kezar Life Sciences does not currently pay dividends.

What is Kezar Life Sciences’s EPS estimate?

Kezar Life Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kezar Life Sciences have?

Kezar Life Sciences has 7,305,800 shares outstanding.

What happened to Kezar Life Sciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kezar Life Sciences?

Currently, no hedge funds are holding shares in KZR

Kezar Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.78%

Trailing 12-Months

Asset Growth

-37.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kezar Life Sciences

Kezar Life Sciences (KZR) is a biotechnology company focused on the discovery and development of novel small molecule therapies to treat unmet needs in autoimmune diseases and cancer. The company is pioneering a new approach to drug discovery using protein degradation and immunoproteasome modulation, with a pipeline that includes both preclinical and clinical-stage programs. Kezar's lead product candidate, KZR-616, is in clinical development for the treatment of multiple autoimmune diseases.

Kezar Life Sciences (KZR) Earnings & Revenues

Historic Earnings Reports

KZR Company Deck

KZR Earnings Call

Q4 2025

0:00 / 0:00

KZR Stock 12 Month Forecast

Average Price Target

$7.00

▲(70.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","6":"$6","9":"$9","4.5":"$4.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,4.5,6,7.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.6000000000000005,4.800000000000001,5,5.2,5.4,5.6000000000000005,5.800000000000001,6,6.2,6.4,6.6,6.800000000000001,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.6000000000000005,4.800000000000001,5,5.2,5.4,5.6000000000000005,5.800000000000001,6,6.2,6.4,6.6,6.800000000000001,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.4,4.6000000000000005,4.800000000000001,5,5.2,5.4,5.6000000000000005,5.800000000000001,6,6.2,6.4,6.6,6.800000000000001,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.38,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >